Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT107 for immune restoration in lymphopenic COVID-19 oncology patients
NCT04426201Phase 2Terminated
- Sponsor
- RevImmune
- Start
- Dec 2020
- Primary completion
- Jun 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of recombinant human interleukin-7 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by RevImmune. Primary endpoint: Improvement of the absolute lymphocyte count at 30 days. Started Dec 2020; status: terminated.
02
Drugs
recombinant human interleukin-7
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04426201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04426201.